BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

734 related articles for article (PubMed ID: 27686171)

  • 1. Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.
    Gardner JA; Peterson JD; Turner SA; Soares BL; Lancor CR; Dos Santos LL; Kaur P; Ornstein DL; Tsongalis GJ; de Abreu FB
    Am J Clin Pathol; 2016 Oct; 146(4):448-55. PubMed ID: 27686171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular genetic evaluation of myeloproliferative neoplasms.
    Azzato EM; Bagg A
    Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
    Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
    Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
    Turakhia SK; Murugesan G; Cotta CV; Theil KS
    J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
    Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
    PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms].
    Lyu XD; Li YW; Guo Z; Xin YP; Hu JY; Fan RH; Song YP
    Zhonghua Nei Ke Za Zhi; 2020 Jan; 59(1):35-39. PubMed ID: 31887834
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients.
    Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Pauwilai T; Singdong R; Rujirachaivej P; Chareonsirisuthigul T; Siriboonpiputtana T
    Hematology; 2017 Dec; 22(10):599-606. PubMed ID: 28406068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
    Rabade N; Subramanian PG; Kodgule R; Raval G; Joshi S; Chaudhary S; Mascarenhas R; Tembhare P; Gujral S; Patkar N
    Indian J Pathol Microbiol; 2018; 61(2):209-213. PubMed ID: 29676359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rare Case of Accelerated-Phase Chronic Myeloid Leukemia Diagnosed During Treatment for JAK2 V617F-Positive Primary Myelofibrosis.
    Ryu J; Chu D; Park B; Kim M; Cho YU; Hwang SH; Jang S; Seo EJ; Lee JH; Park CJ
    Lab Med; 2022 Nov; 53(6):e140-e144. PubMed ID: 35243502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
    Tefferi A
    Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
    Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA
    BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rapid, highly accurate method for quantifying CALR mutant allele burden in persons with myeloproliferative neoplasms.
    Yao QM; Zhou J; Gale RP; Li JL; Li LD; Li N; Chen SS; Ruan GR
    Hematology; 2015 Oct; 20(9):517-22. PubMed ID: 25860380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
    Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
    Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT.
    Poluben LO; Neumerzhytska LV; Klymenko SV; Fraenkel P; Balk C; Shumeiko OO
    Probl Radiac Med Radiobiol; 2020 Dec; 25():362-373. PubMed ID: 33361847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
    Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
    BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
    Kang MG; Choi HW; Lee JH; Choi YJ; Choi HJ; Shin JH; Suh SP; Szardenings M; Kim HR; Shin MG
    Oncotarget; 2016 Aug; 7(35):57036-57049. PubMed ID: 27486987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
    Tefferi A; Guglielmelli P; Larson DR; Finke C; Wassie EA; Pieri L; Gangat N; Fjerza R; Belachew AA; Lasho TL; Ketterling RP; Hanson CA; Rambaldi A; Finazzi G; Thiele J; Barbui T; Pardanani A; Vannucchi AM
    Blood; 2014 Oct; 124(16):2507-13; quiz 2615. PubMed ID: 25037629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.